Last updated: February 20, 2026
What is NDC 16571-0784?
NDC 16571-0784 refers to a specific pharmaceutical product registered in the National Drug Code (NDC) system. Based on available data, this code corresponds to Cephalosporin antibiotics, likely a formulation used for systemic bacterial infections. Exact details such as manufacturer, strength, and packaging can vary; clarification of the specific drug is necessary for precise analysis.
Market Overview
Therapeutic Area and Indications
Cephalosporins have broad-spectrum activity against gram-positive and gram-negative bacteria. They are used for respiratory, urinary tract, skin infections, and surgical prophylaxis. Market demand aligns with bacterial infection prevalence, antibiotic stewardship policies, and evolving resistance patterns.
Competitive Landscape
The market features several generic manufacturers and a handful of branded products. Leading competitors include:
- Sandoz (generic cephalosporins)
- Teva Pharmaceuticals
- Mylan (part of Viatris)
- Pfizer (specific branded formulations)
The generic segment dominates, accounting for approximately 85% of sales volume, driven by cost competitiveness and insurance preferences.
Market Size and Trends
In the U.S., the systemic antibiotics market was valued at approximately USD 8 billion in 2022, with cephalosporins comprising 30-40% of this market. Growth is driven by:
- Rising antibiotic resistance prompting new formulations
- Increased outpatient antibiotic use
- Pandemic-related changes in infection management
Regulatory Environment
- FDA approvals for generic equivalents have increased, expanding market availability.
- Antibiotic stewardship programs restrict overuse, impacting sales volumes.
- Expanding indications and formulations (e.g., oral, IV) create incremental demand.
Price Projections
Historical Pricing
- Brand-name cephalosporins (e.g., Rocephin) have retail prices averaging around USD 60–80 per vial.
- Generics are priced between USD 10–25 per vial, with significant variability based on supplier, volume, and contract dynamics.
- Wholesale acquisition costs (WAC) for common formulations hover around USD 15–20.
Current Price Trends (2023)
- Generic cephalosporins have shown a 5-8% annual decrease due to market saturation and competition.
- Brand-name prices remain stable or slightly increase, influenced by manufacturing costs and supply chain factors.
Future Price Projections (2024–2028)
| Year |
Expected Average Price (per vial) |
Key Factors |
| 2024 |
USD 11–19 |
Increased generic competition, shrinking profit margins |
| 2025 |
USD 10–18 |
Patent expirations open new generic entries |
| 2026 |
USD 9–17 |
Further market consolidation, price stabilization |
| 2027 |
USD 9–16 |
Potential new generic entrants, regulatory pressures |
| 2028 |
USD 8–15 |
Market saturation limits price declines |
The decline is mainly driven by intensified generic competition and healthcare cost containment policies. Costs for raw materials and regulatory compliance could temper deeper price reductions.
Factors Influencing Market and Price
- Antibiotic resistance: growing resistance may reduce prescribed volumes, constraining revenue.
- Supply chain: manufacturing constraints or raw material shortages impact pricing.
- Regulatory actions: new generic approvals and policy changes affect market competitiveness.
- Segment shifts: increased preferences for oral formulations and outpatient therapy may diminish injectable demand.
Summary
NDC 16571-0784, likely a cephalosporin product, operates within a highly competitive generic antibiotic market. Prices are trending downward, driven by rising competition, while overall market demand remains steady but impacted by resistance trends and stewardship policies. Prices could decline to as low as USD 8–15 per vial by 2028, contingent on external factors like regulatory changes or resistance patterns.
Key Takeaways
- The market for products matching NDC 16571-0784 is primarily generic, with robust competition.
- Prices are declining, with an estimated average of USD 10–19 per vial in 2023.
- Future price drops are projected, with stabilization expected around USD 8–15 per vial by 2028.
- Market growth depends on infection prevalence, resistance, and supply chain stability.
- Regulatory and stewardship policies are critical factors affecting supply and prices.
FAQs
1. How does antibiotic resistance affect the market for cephalosporins?
Resistance reduces prescribing, potentially lowering demand. It also encourages development of new formulations and combination therapies, which can alter market dynamics.
2. Are there significant regional differences in pricing?
Yes. U.S. prices tend to be higher than international markets due to regulatory and reimbursement differences. Price declines are more pronounced in competitive markets like the U.S. given regulatory approvals.
3. What are the key drivers for generic competitors entering the cephalosporin market?
Patent expirations, cost advantages in manufacturing, and regulatory pathways facilitate generic entry, driving down prices.
4. How will regulatory changes impact future prices?
Stricter approvals and quality standards may increase costs, potentially limiting price declines. Conversely, streamlined generic approval processes can increase competition and lower prices.
5. What are the primary risks to these price projections?
Emerging resistance, manufacturing disruptions, or policy shifts favoring branded products could alter market dynamics disproportionately.
References
[1] IQVIA. (2022). U.S. pharmaceutical market report.
[2] FDA. (2023). Drug approval and regulatory processes.
[3] Statista. (2023). Antibiotics market size and trends.
[4] Sandoz. (2022). Cephalosporin product portfolio data.
[5] XPharm. (2023). Wholesale acquisition costs overview.
